Sterling Accuris Diagnostics has made a strategic acquisition, integrating Vaibhav Analytical Services into its fold, marking a pivotal move aimed at broadening its spectrum in pharmaceutical analytical testing.

The acquisition targets an expansion of Sterling Accuris’ service repertoire, particularly in pharmaceutical analysis, within the vibrant landscape of Gujarat's pharmaceutical industry. Holding a significant 33 percent stake in drug manufacturing and 28 percent in nationwide drug exports, the pharmaceutical sector in Gujarat remains a key player in India's pharmaceutical domain.

Founded in 1999, Vaibhav Analytical Services specializes in crucial pharmaceutical analyses vital to drug development. Operating an NABL-accredited laboratory in Ahmedabad, the company upholds international benchmarks for pharmaceutical testing while catering to clientele across India. Notably, it holds endorsement by the Nigerian Government (NAFDAC) as a CRIA authorized laboratory, further underlining its credibility and standards adherence.

Rajiv Sharma, MD of Sterling Accuris Diagnostics, affirmed, "This aligns with our steadfast commitment to fostering healthcare progress through innovative diagnostics and analytical testing services."

Ankush Gupta, CEO of Sterling Accuris Diagnostics, emphasized that the inclusion of Vaibhav Analytical would significantly address the escalating demand for comprehensive pharmaceutical testing services.

Gaurang Oza, Partner at Vaibhav Analytical Services, expressed enthusiasm about this collaboration, recognizing it as a milestone for Vaibhav Analytical Services, poised to contribute substantially to advancements in pharmaceutical testing.

The acquisition signals a strategic stride for Sterling Accuris Diagnostics, leveraging Vaibhav Analytical Services' expertise to fortify its footing in pharmaceutical analytical testing while meeting the burgeoning industry demands for quality-driven and innovative diagnostic solutions.